Pre-eclampsia: Connecting angiogenic and metabolic pathways

Trends in Endocrinology and Metabolism

Volumn 21, Issue 9, 2010, Pages 529-536

  Shenoy, Vivek ^a   Kanasaki, Keizo ^a   Kalluri, Raghu ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; CATECHOL METHYLTRANSFERASE; GLYCOGEN; HOMOCYSTEINE; VASCULOTROPIN RECEPTOR 1; VITAMIN B GROUP;

ANGIOGENESIS; HUMAN; METABOLIC DISORDER; METABOLISM; NONHUMAN; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; VITAMIN DEFICIENCY;

CATECHOL O-METHYLTRANSFERASE; ESTRADIOL; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 77956189001     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.05.002     Document Type: Review

References (72)

1. Kanasaki K., Kalluri R. The biology of preeclampsia. Kidney Int. 2009, 76:831-837.
2. Sibai B., et al. Pre-eclampsia. Lancet 2005, 365:785-799.
3. Zhou Y., et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?. J. Clin. Invest 1997, 99:2139-2151.
4. Zhou Y., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am. J. Pathol. 2002, 160:1405-1423.
5. Gilbert J.S., et al. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007, 50:1142-1147.
6. Vuorela P., et al. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet. Gynecol. 2000, 95:353-357.
7. Sugimoto H., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 2003, 278:12605-12608.
8. Maynard S.E., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest 2003, 111:649-658.
9. Levine R.J., et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004, 350:672-683.
10. Levine R.J., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006, 355:992-1005.
11. Venkatesha S., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006, 12:642-649.
12. Salahuddin S., et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am. J. Obstet. Gynecol. 2007, 197:28-36.
13. Moore Simas T.A., et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am. J. Obstet. Gynecol. 2007, 197:244-248.
14. De V.A., et al. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet. Gynecol. Scand. 2008, 87:837-842.
15. Georgiades P., et al. Comparative developmental anatomy of the murine and human definitive placentae. Placenta 2002, 23:3-19.
16. Ain R., et al. Gestation stage-dependent intrauterine trophoblast cell invasion in the rat and mouse: novel endocrine phenotype and regulation. Dev. Biol. 2003, 260:176-190.
17. Karumanchi S.A., Stillman I.E. In vivo rat model of preeclampsia. Methods Mol. Med. 2006, 122:393-399.
18. Lu F., et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am. J. Obstet. Gynecol. 2007, 196:396-397.
19. Suzuki H., et al. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 2009, 54:1129-1135.
20. Li Z., et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007, 50:686-692.
21. Hoff C.M., Margetts P.J. Adenovirus-based transient expression systems for peritoneal membrane research. Perit. Dial. Int. 2006, 26:547-558.
22. Mahasreshti P.J., et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin. Cancer Res. 2003, 9:2701-2710.
23. Koi H., et al. Differential expression of the coxsackievirus and adenovirus receptor regulates adenovirus infection of the placenta. Biol. Reprod. 2001, 64:1001-1009.
24. Stanek J. Acute and chronic placental membrane hypoxic lesions. Virchows Arch. 2009, 455:315-322.
25. Sela S., et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res. 2008, 102:1566-1574.
26. Gilbert J.S., et al. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 2010, 55:380-385.
27. Makris A., et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 2007, 71:977-984.
28. Podjarny E., et al. Animal models of preeclampsia. Semin. Nephrol. 2004, 24:596-606.
29. Hirashima M., et al. Trophoblast expression of fms-like tyrosine kinase 1 is not required for the establishment of the maternal-fetal interface in the mouse placenta. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15637-15642.
30. Zhu B.T. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab. 2002, 3:321-349.
31. Mabjeesh N.J., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3:363-375.
32. Gerber H.P., et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 1997, 272:23659-23667.
33. Barnea E.R., et al. Catechol-O-methyl transferase activity in the human term placenta. Am. J. Perinatol. 1988, 5:121-127.
34. Kanasaki K., et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008, 453:1117-1121.
35. Yan J., et al. 2-methoxyestradiol reduces cerebral vasospasm after 48hours of experimental subarachnoid hemorrhage in rats. Exp. Neurol. 2006, 202:348-356.
36. Barchiesi F., et al. 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ. Res. 2006, 99:266-274.
37. Dubey R.K., et al. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 2001, 37:640-644.
38. Dubey R.K., Jackson E.K. Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol. Metab. 2009, 20:374-379.
39. Takanashi K., et al. Detection and measurement of urinary 2-hydroxyestradiol 17-sulfate, a potential placental antioxidant during pregnancy. Clin. Chem. 2000, 46:373-378.
40. Nackley A.G., et al. Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs. PLoS. One. 2009, 4:e5237.
41. Nackley A.G., et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006, 314:1930-1933.
42. Lee S.B., et al. Preeclampsia. 2-Methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am. J. Pathol. 2010, 176:710-720.
43. Wald D.S., et al. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202.
44. Baksu A., et al. Plasma homocysteine in late pregnancies complicated with preeclampsia and in newborns. Am. J. Perinatol. 2006, 23:31-35.
45. Maruotti G., et al. [Preeclampsia and high serum levels of homocysteine]. Minerva Ginecol. 2005, 57:165-170.
46. Mao, D. et al. (2009) Association of homocysteine, asymmetric dimethylarginine, and nitric oxide with preeclampsia. Arch. Gynecol. Obstet. In press.
47. Hubel C.A. Oxidative stress in the pathogenesis of preeclampsia. Proc. Soc. Exp. Biol. Med. 1999, 222:222-235.
48. Middeldorp S. Thrombophilia and pregnancy complications: cause or association? J. Thromb. Haemost. 2007, 5(Suppl. 1):276-282.
49. Kassab S.E., et al. Hyperhomocysteinemia in pregnant rats: effects on arterial pressure, kidneys and fetal growth. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 122:177-181.
50. Falcao S., et al. Hyperhomocysteinemia is not sufficient to cause preeclampsia in an animal model: the importance of folate intake. Am. J. Obstet. Gynecol. 2009, 200:198-205.
51. Dasarathy J., et al. Methionine metabolism in human pregnancy. Am. J. Clin. Nutr. 2010, 91:357-365.
52. Voutilainen S., et al. Functional COMT Val158Met polymorphism, risk of acute coronary events and serum homocysteine: the kuopio ischaemic heart disease risk factor study. PLoS One 2007, 2:e181.
53. Bridges J.P., et al. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am. J. Hypertens. 2009, 22:564-568.
54. Yung H.W., et al. Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am. J. Pathol. 2008, 173:451-462.
55. Banerjee S., et al. Mouse models for preeclampsia: disruption of redox-regulated signaling. Reprod. Biol. Endocrinol. 2009, 7:4.
56. Braekke K., et al. Homocysteine, cysteine, and related metabolites in maternal and fetal plasma in preeclampsia. Pediatr. Res. 2007, 62:319-324.
57. Guven M.A., et al. Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight. Hypertens. Pregnancy. 2009, 28:190-200.
58. Sanchez S.E., et al. Plasma folate, vitamin B(12), and homocyst(e)ine concentrations in preeclamptic and normotensive Peruvian women. Am. J. Epidemiol. 2001, 153:474-480.
59. Herrmann W., et al. Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status. Clin. Chem. Lab. Med. 2005, 43:1139-1146.
60. Wen S.W., et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am. J. Obstet. Gynecol. 2008, 198:45-47.
61. Ray J.G., Laskin C.A. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. Placenta 1999, 20:519-529.
62. Robb S.A., Hytten F.E. Placental glycogen. Br. J. Obstet. Gynaecol. 1976, 83:43-53.
63. Bloxam D.L., et al. Placental glycolysis and energy metabolism in preeclampsia. Am. J. Obstet. Gynecol. 1987, 157:97-101.
64. Arkwright P.D., et al. Pre-eclampsia is associated with an increase in trophoblast glycogen content and glycogen synthase activity, similar to that found in hydatidiform moles. J. Clin. Invest 1993, 91:2744-2753.
65. Leonce J., et al. Glucose production in the human placenta. Placenta 2006, 27:S103-S108.
66. Longo L.D., et al. Anaerobic, glycogen-dependent transport of amino acids by the placenta. Nature 1973, 243:531-533.
67. Rademacher T.W., et al. Preeclampsia, insulin signalling and immunological dysfunction: a fetal, maternal or placental disorder?. J. Reprod. Immunol. 2007, 76:78-84.
68. Liao R., et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 2002, 106:2125-2131.
69. Omar M.A., et al. Cardioprotection by GSK-3 inhibition: role of enhanced glycogen synthesis and attenuation of calcium overload. Cardiovasc. Res. 2010, 86:478-486.
70. Ramirez J.M., et al. Hypoxia tolerance in mammals and birds: from the wilderness to the clinic. Annu. Rev. Physiol. 2007, 69:113-143.
71. Voros G., Lijnen H.R. Role of placental growth factor in glucose metabolism. J. Thromb. Haemost. 2006, 4:2098-2099.
72. Coan P.M., et al. Origin and characteristics of glycogen cells in the developing murine placenta. Dev. Dyn. 2006, 235:3280-3294.